Skip to content

Pharmacokinetic Study of CD25 Monoclonal Antibody in the Treatment of Steroid-Resistant aGVHD in Children

Pharmacokinetic study of recombinant anti-CD25 humanized monoclonal antibody in treating pediatric patients with steroid-refractory aGVHD after allo-HSCT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126063
Enrollment
Unknown
Registered
2026-06-03
Start date
2026-02-25
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid-refractory aGVHD

Interventions

Group of CD25 Ab:CD25 monoclonal antibody

Sponsors

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age 0–18 years, regardless of gender; 2. Undergoing allogeneic hematopoietic stem cell transplantation; 3. Diagnosed with glucocorticoid-resistant aGVHD according to the "Chinese Expert Consensus on Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Diseases (III) — Acute Graft-versus-Host Disease (2024 Edition)"; 4. The guardian of the subject fully understands the clinical trial protocol, agrees to participate in the trial, and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular and cerebrovascular diseases: patients with heart function classified as grade 3 or below;those with a history of coronary heart disease, cerebral thrombosis, or cerebral arteriosclerosis; 2. Patients showing signs of relapse through bone marrow morphology, genetic testing, or immunological examination;or patients with malignant tumors whom doctors judge are at risk of relapse within the next 100 days. 3. Severe liver or kidney dysfunction: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN), or total bilirubin (TBIL) >5 times ULN, or prothrombin activity (PTA) 3 times ULN; 4. Patients with severe organ failure, ECOG score greater than 2; 5. Patients with severe infections, CMV viremia, or positive plasma EBV; 6. Any other conditions deemed by the investigator to make participation in this study inappropriate.

Design outcomes

Primary

MeasureTime frame
Serum drug concentration of CD25 Ab;

Secondary

MeasureTime frame
Chronic GVHD rate;Outcome of Acute GVHD;

Countries

China

Contacts

Public ContactWenyu Yang

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

yangwenyu@ihcams.ac.cn+86 22 23909138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026